Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.
Hum Immunol
; 81(12): 697-701, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-838428
ABSTRACT
SARS-CoV2 might conduce to rapid respiratory complications challenging healthcare systems worldwide. Immunological mechanisms associated to SARS-CoV2 infection are complex and not yet clearly elucidated. Arguments are in favour of a well host-adapted virus. Here I draw a systemic immunological representation linking actual SARS-CoV2 infection literature that hopefully might guide healthcare decisions to treat COVID-19. I suggest HLA-G and HLA-E, non classical HLA class I molecules, in the core of COVID-19 complications. These molecules are powerful in immune tolerance and might inhibit/suppress immune cells functions during SARS-CoV2 infection promoting virus subversion. Dosing soluble forms of these molecules in COVID-19 patients' plasma might help the identification of critical cases. I recommend also developing new SARS-CoV2 therapies based on the use of HLA-G and HLA-E or their specific receptors antibodies in combination with FDA approved therapeutics to combat efficiently COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Histocompatibility Antigens Class I
/
HLA-G Antigens
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Hum Immunol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS